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Summary
Objective: Diacerein has proved to be effective in the treatment of osteoarthritis (OA). However, the precise action mechanism of diacerein
on OA is not yet fully understood. Therefore, we investigated the effects of rhein, an active metabolite of diacerein, on the production of
promatrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase-1 (TIMP-1) in rabbit articular chondrocytes.
Design: Confluent rabbit chondrocytes were treated for 24 or 48 h with rhein, naproxen or dexamethasone in the presence of recombinant
human IL-1 (rhIL-1). ProMMP-9/progelatinase B in the culture medium was monitored by gelatin zymography, and proMMP-1/
procollagenase 1, proMMP-3/prostromelysin 1, proMMP-13/procollagenase 3 and TIMP-1 were analysed by Western blot analysis. The
steady-state levels of proMMP mRNAs were examined by Northern blot analysis. Total MMPs activity was also determined using
FITC-labeled casein.
Results: Rhein suppressed the rhIL-1-induced production of proMMPs-1, -3, -9 and -13 in a dose-dependent manner (0.1–30 M). The
suppressed production of proMMPs-1 and -3 was accompanied by a decrease in the steady-state levels of their mRNAs. Interestingly, rhein
increased the production of TIMP-1. These observations were further supported by the fact that rhein decreased the apparent total activity
of MMPs in the culture medium.
Conclusion: We have demonstrated that rhein, an active metabolite of diacerein down-regulates the gene-expression and production of
proMMPs and up-regulates the TIMP-1 production. The therapeutic effects of diacerein on OA may be due, at least in part, to the
chondroprotective effect of rhein, its active metabolite. © 2001 OsteoArthritis Research Society International
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Osteoarthritis (OA) is a degenerative process of the joints
characterized by progressive destruction and erosion of
cartilage associated with an osteophytic response. This
destruction results from a homeostatic imbalance between
the matrix synthesis and degradation in the cartilage.
Numerous studies have demonstrated that matrix metallo-
proteinases (MMPs) are most frequently implicated in the
destruction of articular cartilage in arthritic diseases1,2.
MMP-1/collagenase 1, MMP-3/stromelysin 1, MMP-9/
gelatinase B and MMP-13/collagenase 3 have been
detected in the synovium, synovial fluid, and cartilage
samples with rheumatoid arthritis (RA) and with OA, and
closely participate in the pathologic loss of articular
cartilage3–8. Furthermore, pro-inflammatory cytokines,257which are produced by monocytes/macrophages, synovial
cells or chondrocytes in the arthritic area of the joint,9
induce and/or augment the production of proMMPs10–12.
The activities of MMPs are controlled at several steps
including proenzyme activation and inhibition by tissue
inhibitors of metalloproteinases (TIMPs)13. Therefore, the
resultant excess molar of MMPs over TIMPs is important
during the cartilage breakdown in arthritic diseases14.
Clinical studies have suggested that diacerein (4,5-
diacetoxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic
acid) exerts a beneficial effect on the symptoms of OA15–17.
The modes of action of diacerein toward OA have been
examined by many investigators; e.g. diacerein shows
anti-osteoarthritic and chondroprotective effects in animal
OA models18,19, and augments hyaluronan synthesis in
synovial cells20. Diacerein also prevents cartilage break-
down by a reduction of the proinflammatory cytokines21.
Diacerein is known to be completely metabolized by ani-
mals and humans into rhein (4,5-dihydroxy-9,10-dioxo-
9,10-dihydroanthracene-2-carboxylic acid) which is an
active metabolite of diacerein22, and rhein reduces the
production of superoxide anion in human neutrophils23.
However, the exact mechanisms of the therapeutic action
of diacerein on OA are not clear.
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CULTURE OF RABBIT ARTICULAR CHONDROCYTES
Articular chondrocytes were isolated by the method of
Green24 with slight modifications from the shoulder and
knee joints of 3-week-old female Japanese White rabbits
(Tokyo Experimental Animal, Tokyo, Japan). Cartilage was
digested with 0.125% trypsin (Difco Laboratories, Detroit,
MI) for 1 h and with 0.1% collagenase (Worthington
Biochemical, Freehold, NJ) for 2 h. Chondrocytes were
then suspended in Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies Inc., Rockville, MD) with 10%
fetal bovine serum (FBS; BioWhittaker, Walkersville, MD)
and antibiotics (100 units/mL penicillin, 100 g/mL strepto-
mycin and 250 ng/mL fungizone®, Life Technologies). The
chondrocytes were cultured in 24-multiwell tissue culture
plates (FALCON®, Becton Dickinson Labware, Franklin
Lakes, NJ) or in 100-mm tissue culture dishes (Iwaki Glass,
Chiba, Japan) at a density of 2.5×104 cells/cm2 in 5%
CO2-95% air at 37°C. Primary cultures maintained in a
monolayer were used throughout the study. After cells
reached confluence, the medium was changed to DMEM
with 0.2% lactalbumin hydrolysate (Sigma Chemical, St
Louis, MO) and the antibiotics. Confluent chondrocytes
were then incubated with rhein sodium salt (Kyowa Hakko
Kogyo, Tokyo, Japan), naproxen (Sigma) or dexametha-
sone (Sigma) in the presence of 1 ng/mL of recombinant
human IL-1 (rhIL-1; Genzyme, Cambridge, MA) for 24 or
48 h. To make stock solutions, rhein sodium salt was
dissolved in distilled water at 3×10−2 M, and naproxen
and dexamethasone were dissolved in dimethyl sulfoxide
at 1×10−1 M, and they were added to the cell culture at
appropriate concentrations. The final concentrations of
distilled water and dimethyl sulfoxide were 0.1% and
0.01%, respectively. The concentrations of rhein used were
chosen to reflect levels that are below, at, or above the
established therapeutic antiinflammatory serum values of
rhein after dosing with diacerein as described in clinical
practice22,25, since diacerein is known to be completely
metabolized into rhein22. The harvested culture media were
stored at −40°C until use.GELATIN ZYMOGRAPHY
ProMMP-9 in the conditioned medium was detected by
gelatin zymography as previously described26. The
samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) using a
10% acrylamide gel containing 0.6 mg/mL of gelatin (Difco
Laboratories) under non-reducing conditions at 4°C. After
electrophoresis, SDS in the gel was removed by rinsing
with 50 mM Tris-HCl, 5 mM CaCl2, 1 M ZnCl2, 0.02%
NaN3, and 2.5% Triton-X 100 (pH 7.5). The gel was then
incubated for 2 h at 37°C in the same buffer without
Triton-X 100. After incubation, the gel was stained with
0.1% Coomassie brilliant blue R250 (Bio-Rad Laboratories,
Hercules, CA) in 50% methanol/20% acetic acid, and
destained with 1% formic acid/30% methanol. The gelatino-lytic activity was analysed using National Institute of Health
Image software (NIH, Bethesda, MD).WESTERN BLOT ANALYSIS
The levels of MMPs-1, -3, -13 and TIMP-1 in the con-
ditioned medium were analysed by Western blot analysis.
Sheep anti-(rabbit proMMP-1 or proMMP-3) antibody, or
sheep anti-(human TIMP-1) antibody were prepared as
previously described27,28 and rabbit anti-(human proMMP-
13) antibody was kindly provided by Dr P. Mitchell29. The
collected conditioned medium was subjected to SDS-PAGE
with 12.5% (proMMP-1 and TIMP-1) or 10% (proMMP-
3 and proMMP-13) acrylamide gels under reducing
conditions. After electrophoresis, proteins in the gel
were electrotransferred onto a nitrocellulose membrane
(Protran®; Schleicher and Schuell, Dassel, Germany). The
membrane was then blocked, washed, and incubated over-
night with sheep anti-(rabbit proMMP-1 or proMMP-3) anti-
body, rabbit anti-(human proMMP-13) antibody or sheep
anti-(human TIMP-1) antibody which was then complexed
with alkaline phosphate conjugated donkey anti-sheep IgG
(Sigma) for 2 h or peroxidase conjugated anti-rabbit
or -sheep IgG (Sigma) for 1 h. The immunoreactive
proMMP-1 and proMMP-3 were indirectly visualized using
5-bromo-4-chloro-3-indolyl phosphate (Sigma) and nitro
blue tetrazolium (Sigma) (Conventional Western blotting)
as previously described30, and proMMP-13 and TIMP-1
were monitored by enhanced chemiluminescence (ECL)-
Western blotting detection reagents (Amersham Pharmacia
Biotech, Tokyo, Japan) as previously described31.ASSAY FOR CASEINOLYTIC ACTIVITY OF MMPS
The apparent MMPs activity in the conditioned medium
was determined using FITC-labeled casein as a substrate,
according to the method of Twining32, with slight modifi-
cations for microassay. Before the assay, proMMPs in the
conditioned medium were activated by TPCK treated-
trypsin (0.1 mg/mL, Worthington Biochemical) followed
by the addition of four molar excess of soybean trypsin
inhibitor (Life Technologies). The culture medium (80 L)
and 0.5% FITC-labeled casein were incubated in a total
130 L of 0.5 M Tris-HCl, pH 7.2, for 42 h at 37°C. After the
incubation the reaction was terminated by adding trichloro-
acetic acid at final concentration of 6.8%. The mixtures
were centrifuged at 4°C and 2000 rpm for 15 min. A portion
(50 L) of the supernatant was mixed with 200 L of the
assay buffer (0.5 M Tris-HCl, pH 8.5), and fluorescence
was subsequently measured at 485 nm excitation and
530 nm emission wavelengths using a Cyto FluorY fluor-
escence multiwell plate reader (PerSeptive Biosystems,
Tokyo, Japan). The enzyme activity that digests 1 g of
casein for 1 h at 37°C was expressed as one unit.NORTHERN BLOT ANALYSIS
The steady-state levels of proMMP mRNA were deter-
mined by Northern blot analysis as previously described33.
Complementary DNA of human proMMP-1 (1.6 kb) and
human proMMP-3 (1.4 kb) were prepared as previously
described34. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA was purchased from Clontech Laborato-
ries (Palo Alto, CA). Human proMMP-1, human proMMP-3
or GAPDH cDNA was labeled with [-32P]dCTP (DuPontTherefore, we investigated the effects of rhein, an active
metabolite of diacerein, on the production of pro-MMPs
including proMMPs-1, -3, -9 and -13 and TIMP-1 in rabbit
articular chondrocytes to obtain further insight into the
clinical application of this agent.
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(Boehringer Mannheim, Indianapolis, IN). Total cytoplasmic
RNA was extracted using ISOGEN (Nippon Gene Co.,
Toyama, Japan) according to the manufacturer’s instruc-
tions and stored at −80°C. The isolated RNA (20 g) was
denatured and electrophoresed on 1% formaldehyde-
denatured agarose gel and then transferred onto a nylon
membrane (GeneScreen; NENY Life Science Products,
Boston, MA). The membrane was hybridized with each
32P-labeled cDNA for proMMPs-1, -3 or GAPDH probe at
42°C in the hybridization solution containing 50% forma-
mide, 5×saline sodium citrate (SSC), 100 g/ml denatured
salmon sperm DNA, 1×Denhard’s solution, and 0.1% SDS.
After hybridization, the membrane was sequentially
washed in 2×SSC/0.1% SDS at room temperature and
subjected to autoradiography using Konica medical X-ray
film (Konica Co., Tokyo, Japan) at −80°C. The resulting
autoradiogram was analysed with NIH Image software and
normalized to the relative intensities of the corresponding
GAPDH band.STATISTICAL ANALYSIS
The values of MMPs activity determined in the con-
ditioned medium were expressed as the mean with stan-
dard deviation for each group. The comparison was
analysed by F test followed by Aspin–Welch test. Multiple
comparisons between treatment groups were assessed by
a one-way analysis of variance followed by Dunnett’s test.
A P-value of less than 0.05 was considered to be statisti-
cally significant.ResultsEFFECTS OF RHEIN ON THE RHIL-1-INDUCED PROMMPS-9, -1, -3,
-13 AND TIMP-1 PRODUCTION
Gelatin zymography indicated that rabbit articular
chondrocytes spontaneously produced small amounts of
proMMP-9. When confluent chondrocytes were treated
with rhIL-1 (1 ng/mL) for 48 h, the level of proMMP-9 in
the conditioned medium increased by about five-fold as
compared with that of the untreated control cells (Fig. 1).
Rhein suppressed the rhIL-1-induced proMMP-9 produc-
tion in a dose-dependent manner (0.1–30 M) with amaximal inhibition of 98% at 30 M. Dexamethasone
(1–100 nM) effectively suppressed the production of
proMMP-9, whereas naproxen (0.1–10 M) enhanced it.
We further examined the effects of rhein on the rhIL-1-
induced production of proMMPs-1, -3 and -13 by Western
blot analysis. As shown in Fig. 2, rhIL-1 (1 ng/mL) mark-
edly increased the secreted protein level of proMMPs-1, -3
and -13. Rhein inhibited the production of proMMPs-1, -3
and -13 in a dose-dependent manner (3–30 M) with
maximum 88, 82 and 100% inhibitions at 30 M, respect-
ively. Dexamethasone also suppressed the production of
these proMMPs in a dose-dependent manner (1–100 nM).
By contrast, naproxen (1–10 M) slightly enhanced the
production of proMMPs-1 and -3, but not proMMP-13.
Next, we investigated the effect of rhein on the TIMP-1
production by Western blot analysis. When confluent
chondrocytes were treated with rhIL-1 (1 ng/mL) for 24 h,
the production of TIMP-1 increased by about three-fold as
compared with that of the untreated control cells (Fig. 3).
Neither naproxen nor dexamethasone modulated the
TIMP-1 production. By contrast, rhein further augmented
the rhIL-1-induced TIMP-1 production in a dose-
dependent manner (10–30 M) with a maximum augmen-
tation of 222% at 30 M.Fig. 1. Effects of rhein, naproxen and dexamethasone on the production of proMMP-9. Confluent chondrocytes in 24-well plates were treated
with rhIL-1 (1 ng/mL) in the presence and absence of the indicated drug for 48 h, and then the conditioned culture medium was subjected
to gelatin zymography as described in the text. Three independent experiments using cells of different origins were highly reproducible, and
typical data are shown. The relative amounts of proMMP-9 were quantified by densitometric scanning and shown at the top of the panels by
taking the rhIL-1-treated cells as 100. Napro; naproxen and Dexa; dexamethasone.EFFECTS OF RHEIN ON THE RHIL-1-ENHANCED CASEINOLYTIC
ACTIVITY OF MMPS
Since the expression of the MMP activities depends on
the balance between MMPs and TIMPs, we investigated
whether the effects of rhein resulted in a decrease in the
apparent MMPs activity. The proMMPs in the conditioned
medium were activated by exposure to TPCK-treated
trypsin. Recombinant hIL-1 (1 ng/mL) significantly aug-
mented the caseinolytic activity compared with the
untreated control (P<0.0001 at 24 h and P=0.0001 at 48 h)
(Table I). Rhein (30 M) significantly suppressed the rhIL-
1-enhanced activity (P=0.0058, 39% inhibition at 24 h
and P=0.0241, 36% inhibition at 48 h). Dexamethasone
(10 nM) also showed significant inhibition (P=0.0002, 62%
inhibition at 24 h and P=0.0050, 32% inhibition at 48 h)
whereas naproxen (1 M) had no effect. In addition, it was
investigated whether rhein had a direct inhibitory effect on
the caseinolytic activity. The culture medium of rhIL-1-
treated chondrocytes was used as a source of enzyme
and was TPCK-treated trypsin to activate proMMPs. Rhein
260 T. Tamura et al.: Chondroprotective effects of Diacereindid not directly modulate the caseinolytic activity (data not
shown). These results further supported the fact that
both rhein and dexamethasone inhibited the production of
proMMPs.RHEIN SUPPRESSES THE RHIL-1-INDUCED EXPRESSION OF
PRO-MMP MRNA
We further investigated whether the suppression by
rhein of the production of proMMPs-1 and -3 was due to the
changes in their mRNAs. When confluent rabbit articular
chondrocytes were treated with rhIL-1 (1 ng/mL) for 24 h,the expression of proMMPs-1 or -3 mRNA were signifi-
cantly augmented (Fig. 4). Rhein (30 M) down-regulated
the expression of proMMP-1 and -3 mRNAs (50 and 63%
inhibition, respectively). Dexamethasone (10 nM) also
interfered with their expression (69 and 82% inhibition,
respectively), but naproxen (1 M) did not.Fig. 2. Effects of rhein, naproxen and dexamethasone on the production of proMMPs-1, -3 and -13. ProMMP-1 and proMMP-3; confluent
chondrocytes in 24-well plates were treated with rhIL-1 (1 ng/mL) in the presence and absence of the indicated drug for 48 h. The culture
medium was subjected to conventional-Western blot analysis as described in the text. Pro-MMP-13; Confluent chondrocytes in 100-mm
dishes were treated with rhIL-1 (1 ng/mL) and drugs for 24 h. The culture medium was subjected to ECL-Western blot analysis as described
in the text. Three independent experiments using cells of different origins were highly reproducible, and typical data are shown. The relative
amounts of pro-MMPs-1, -3 and -13 were quantified by densitometric scanning and shown at the top of the panels by taking the
rhIL-1-treated cells as 100. Napro; naproxen and Dexa; dexamethasone.Fig. 3. Effects of rhein, naproxen and dexamethasone on the production of TIMP-1. Confluent chondrocytes in 100-mm dishes were treated
with rhIL-1 (1 ng/mL) in the presence and absence of the indicated drug for 24 h. The culture medium was subjected to ECL-Western blot
analysis as described in the text. Five independent experiments using cells of different origins were highly reproducible, and typical data are
shown. The relative amounts of TIMP-1 were quantified by densitometric scanning and shown at the top of the panels by taking the
rhIL-1-treated cells as 100. Napro; naproxen and Dexa; dexamethasone.Discussion
Cartilage destruction is a crucial feature of OA and is
generally considered irreversible. Accordingly, drugs that
block the destruction of cartilage will be of therapeutic
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Effects of rhein, naproxen and dexamethasone on the rhIL-1-induced caseinolytic activity
Incubation
time
Treatment Conc.
(M)
Caseinolytic activity
(units/mL)
24 h None — 0.45±0.05
rhIL-1 — 1.32±0.09(a)
rhIL-1+Rhein 3 1.25±0.06
rhIL-1+Rhein 10 1.13±0.26
rhIL-1+Rhein 30 0.98±0.06†
rhIL-1+Naproxen 1 1.21±0.14
rhIL-1+Dexamethasone 0.01 0.78±0.16(c)
48 h None — 0.65±0.27
rhIL-1 — 1.72±0.15(b)
rhIL-1+Rhein 3 1.80±0.12
rhIL-1+Rhein 10 1.59±0.11
rhIL-1+Rhein 30 1.33±0.08*
rhIL-1+Naproxen 1 1.69±0.11
rhIL-1+Dexamethasone 0.01 1.38±0.13(d)
Confluent chondrocytes in 100-mm dishes were treated with rhIL-1 (1 ng/mL) in the presence and absence of
an indicated drug for 24 or 48 h. MMPs activities in the conditioned medium were determined using FITC-labeled
casein as described in the text. Values represent means±S.D. for five independent experiments. (a) and (b),
significantly different from untreated control group by Aspin–Welch test (P<0.0001 and P=0.0001, respectively).
(c) and (d), significantly different from rhIL-1-treated control group by Aspin–Welch test (P=0.0002 and
P=0.0050, respectively). * and †, significantly different from rhIL-1-treated control group by Dunnett’s test
(P=0.0241 and P=0.0058, respectively).Fig. 4. Effects of rhein, naproxen and dexamethasone on the steady-state mRNA levels of proMMP-1, proMMP-3 and GAPDH. Confluent
chondrocytes in 100-mm dishes were cultured with rhIL-1 (1 ng/mL) in the presence and absence of the indicated drug for 24 h. Total RNA
(20 g) was subjected to Northern blot analysis as described in the text. The same blot was stripped and reprobed with a GAPDH-encoding
probe to confirm equal lane loadings. Two independent experiments using cells of different origins were highly reproducible, and
representative data are shown. The relative amounts of proMMPs-1 and -3 mRNA were quantified by densitometric scanning and normalized
to GAPDH mRNA by taking the rhIL-1-treated cells as 100. Napro; naproxen and Dexa; dexamethasone.
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ment of OA involves the use of non-steroidal anti-
inflammatory drugs (NSAIDs), analgesics and hyaluronan,
which provide symptomatic relief but exert no apparent
disease-modifying effect35,36. In some instances, NSAIDs
may even be deleterious; they have been reported to inhibit
the synthesis of aggregating proteoglycan, which plays a
crucial role in maintaining the function of the cartilage37.
Therefore, there is a critical need to develop alternative
agents that prevent the destruction of cartilage and/or
stimulate its proper repair.
Diacerein has proved to be effective and well tolerated in
the long-term treatment of OA15–17 and it is currently under
evaluation as a disease modifying OA drug in randomized
placebo-controlled clinical trials of patients with OA of the
hip and knee. The efficacy of diacerein has been well
documented in animal models, including the post-contusive
rabbit model and the accelerated canine model of OA18,19,
but its precise mechanism of action on chondroprotection
is unclear. To obtain further insight into the effects of
diacerein, monolayer cultures of rabbit articular chondro-
cytes were used to investigate the effect of rhein, an active
metabolite of diacerein, on the production of proMMPs and
TIMP-1.
The activities of MMPs in tissues are regulated by a
number of factors, including gene expression of proMMPs,
extracelluar activation of proMMPs and inhibition of MMPs
by their endogenous inhibitors of TIMPs. It is thought that
much of the cartilage destruction seen in OA was found to
be due to a local imbalance between activated MMPs and
TIMPs14. In this communication, we have shown that rhein
suppresses the rhIL-1-induced production of proMMPs-1,
-3, -9 and -13, along with a decrease in their mRNA
expression. By contrast, rhein increased TIMP-1 produc-
tion, suggesting that rhein reduces MMP activities at the
inflammatory site; in fact rhein reduced the apparent
caseinolytic activity in the culture media which precisely
reflected the balance between MMPs and TIMPs. In
addition, this is the first evidence that chondroprotective
drugs including rhein and NSAIDs down-regulate the
proMMP-13 production in articular chondrocytes.
The mechanisms by which rhein inhibits the production
and gene expression of proMMPs are not clear at present.
From this point of view, it is of interest that the up-regulation
of collagenase gene expression by IL-1 is likely to be
mediated by the transcription factors, c-fos and c-jun, and
the activation of activator protein-1 (AP-1) activity38. In
addition, it is also suggested that reactive oxygen species
(ROS) such as hydroxyl radicals, hydrogen peroxide,
superoxide and nitric oxide act as intracellular signaling
molecules mediating the biological effects of cytokines39.
The blocking of the ROS production or decreasing ROS
levels is known to reduce the IL-1-induced c-fos and
collagenase expression in chondrocytes39. The partici-
pation of intracelluar cAMP in the regulation of production
of proMMPs including proMMPs-1, -3 and -9 is also
reported in rabbit articular chondrocytes26 and human
synovial fibroblasts40,41. The actions of rhein and/or its
mother compound of diacerein on the above signals are not
fully understood; in bovine articular chondrocytes diacerein
inhibits AP-1 activity and thereby results in the suppression
of collagenase expression but the action of rhein is not
specified42. Rhein is reported to reduce the production of
superoxide anion in human neutrophils23. Taken together, it
is likely that rhein modulates the production of proMMPs
and TIMP-1 via interference with multiple signaling path-
ways in rabbit chondrocytes. Further studies are needed toelucidate the precise mechanism of action of rhein on the
production of proMMPs and TIMPs in chondrocytes.
In conclusion, we have demonstrated for the first time
that rhein, an active metabolite of diacerein down-regulates
the gene-expression of proMMPs-1 and -3, and the pro-
duction of proMMPs-1, -3, -9 and -13, and furthermore,
it up-regulates the TIMP-1 production. The therapeutic
effects of diacerein on OA and those observed in several
animal models of OA may be due, at least in part, to the
chondroprotective effect of rhein, its active metabolite.References
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